- Add this to...
- Añadir en...
- Favorites
- Delicious
- Digg
- Google Bookmarks
Fact Sheet
National Tuberculosis Indicators Project (NTIP): Frequently Asked Questions
How will NTIP be integrated into the cooperative agreement reporting process?
The national TB program objectives established in 2006 will be included as guidance in the 2010 cooperative agreement. Using the data that are submitted to CDC, NTIP will provide program areas with reports of their performance on achieving these objectives. Program areas will use these reports to complete their interim and annual progress reports to CDC, as well as in their applications for continued funding.
How do the national TB program objectives compare to the 7 performance objectives in the 2005 cooperative agreement announcement on which programs are currently expected to report?
Most national TB program objectives are similar to the 7 performance objectives in the 2005 cooperative agreement. However, the national TB program objectives include a set of standardized indicators and calculations for measuring performance and progress. The national TB program objectives also include new objectives and measures (e.g., TB case rates [U.S.-born persons, foreign-born persons, and children younger than 5 years of age], treatment initiation, data reporting, sputum culture conversion, recommended initial therapy, universal genotyping, and sputum culture reporting) that are important to TB control. Data for these objectives are already being collected; monitoring progress on these objectives will enhance the programs’ abilities to improve program outcomes.
When will NTIP be available for TB programs (state/county)?
NTIP reports will be available to all TB programs funded through the cooperative agreement in the winter of 2008. Programs are strongly encouraged to pilot NTIP in 2009 for progress reporting to CDC, and provide feedback on the process before the formal NTIP implementation in 2010. Additionally, Division of Tuberculosis Elimination will be providing NTIP reports for some counties with high TB incidence. The date for this rollout has not been determined.
How will TB programs be expected to use NTIP reports?
NTIP is a service for TB programs. In addition to using NTIP reports for completing cooperative agreement reporting and prioritizing efforts for program improvements, programs are encouraged to use the information provided to assist with their program planning, education, and outreach. These reports can be used to facilitate discussion and encourage problem solving among staff and with community partners. DTBE consultants will be using NTIP reports to work with programs and to provide appropriate technical assistance.
Do programs have to provide progress report on all national TB program objectives? Or can they pick and choose which objectives to report?
NTIP will provide quantitative progress reports on all objectives. Programs should provide context and comment on the performance described in NTIP. The focus of progress reporting should remain on communicating pertinent issues, concerns, and challenges faced by the program on objectives on which they are not doing well. Most importantly, the program should elaborate on its plan to better understand the barriers and improve the performance. Programs are encouraged to identify other objectives that are important to monitor for their specific programs, and share progress and updates with CDC.
How does NTIP change the progress reporting for programs?
Reporting progress on objectives has been a standard operating procedure for TB programs. NTIP reports are being provided as a service to programs, thus reducing burden on program staff from having to calculate indicators and generate reports. In addition, NTIP provides standard definitions, indicators, and calculations such that all TB programs in the United States are using data consistently to assess progress toward achieving the national objectives and performance targets.
Will programs be able to set their own performance targets?
Yes. The national performance targets are provided as guidance. Achieving the national performance targets will not be feasible for all the programs. TB programs will continue to work with their program consultants to set performance targets based on what is feasible to them.
How will DTBE use NTIP?
DTBE will use NTIP data to assess national progress toward achieving objectives and established performance targets. Program consultants will use NTIP data to monitor program performance, assess needs for education and technical assistance, and work jointly with programs to plan program improvement efforts.
Will NTIP be used to determine funding/resource allocations?
No. Cooperative agreement funding for the recipients will continue to be based on the formula established by the CDC/NTCA work group. However, programs are encouraged to use NTIP reports to inform their planning process and allocation of resources within their programs, or to advocate for additional needed resources.
What kind of support or assistance can we expect from DTBE?
Training on NTIP will be provided at the regional meetings and the CDC Program Managers’ Course, and via webinars. All requests for assistance in using and interpreting NTIP reports should be directed to your program consultant. As necessary, other DTBE staff will be consulted to provide additional assistance.
How is NTIP different from the evaluation that we are doing?
NTIP is a monitoring system using standardized indicators and calculations to track progress toward national objectives. Program evaluation is the systematic examination of the processes that are done to better understand the factors that contribute to program outcomes. NTIP reports will be useful to programs in assisting them to identify areas in need of improvement, thus helping to focus program evaluation activities.
Will NTIP replace the current evaluation requirement?
No. NTIP can be used to help programs identify areas in need of improvement; however, understanding why the program is doing well or poorly requires a more in-depth examination of the process. Evaluation planning assists the program in thinking through the evaluation process before investing resources in the activity.
If we know where we are falling behind, will evaluation be necessary before we can implement changes?
Program evaluation should be conducted to gain the understanding of why program objectives are not being met and to inform changes. When sufficient information is available to make informed decisions regarding program improvements, evaluation activities should be focused on another area where information for decision-making is needed.
Will programs be expected to write an evaluation plan for every objective for which they didn’t meet the target?
No. Programs will continue to be expected to address one priority objective through evaluation. The program consultant should be actively engaged in the selection of the objective to be addressed.
Will an evaluation plan be required before any evaluation can be done?
Yes. Program evaluation requires program resources. As with any activity requiring resources, a plan should be developed to anticipate issues and problems, and thus ensure that resources are used effectively.
How often will the evaluation be required? Will CDC establish timelines?
To be useful and feasible, program evaluations must be tailored to the program’s needs. While programs will continue to be expected to routinely conduct program evaluations, the specifics and timelines of the evaluations will be established in consultation with the program consultants.
Additional Information
The National Tuberculosis Indicators Project (NTIP)
Contact Us:
- Centers for Disease Control and Prevention
Division of Tuberculosis Elimination (DTBE)
1600 Clifton Rd., NE
MS E10
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - Contact CDC–INFO
Tuberculosis
- Topics
- Basic TB Facts
- Treatment
- Testing & Diagnosis
- TB & HIV Coinfection
- Infection Control & Prevention
- Drug-Resistant TB
- TB in Specific Populations
- African-American Community
- Children
- Correctional Facilities
- Table of Contents
- Introduction
- Strengthen TB Information Systems and Program Assessment
- Strengthen TB Environmental Controls and Isolation Practices
- Provide More Comprehensive and Timely Screening and Diagnostic Evaluations
- Develop and Strengthen Contact Investigation Protocols
- Increase HIV Counseling and Testing
- Increase Staff Training
- Strengthen Collaboration Between Health Departments and Jails
- Homelessness
- International Travelers
- Pregnancy
- Vaccines & Immunizations
- Laboratory Information
- Drug Susceptibility Testing
- The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TB
- Rapid Molecular Testing to Detect Drug-Resistant TB in the US
- Executive Summary
- Introduction
- Background on Tests for Molecular Detection of DR
- General Considerations and Principles for a Molecular DR Testing Service
- Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
- Research Needs
- General Recommendations of the Expert Panel
- Communication Plan for the Report
- Recommendations
- References
- Panel Members and CDC Participants
- Appendix 1
- Appendix 2
- Appendix 3
- Interim Laboratory Biosafety Guidance for XDR Mycobacterium tuberculosis strains
- Research
- TB Epidemiologic Studies Consortium
- Background
- Infrastructure
- Research Projects
- Publications
- Meetings
- Directory
- TBESC Committee Members
- Translating Research into Practice (TRIP)
- Contact TBESC
- Prospective Evaluation of Immunogenetic and Immunologic Markers for Susceptibility to Tuberculosis Infection and Progression from M. Tuberculosisinfection to active TB
- Zero Tolerance for Pediatric TB
- Models for Incorporating HIV Counseling, Testing, and Referral into Tuberculosis Contact Investigations
- Prevalence of Latent TB Infection Among High Risk Populations in the United States
- Regional Capacity-Building in Low-Incidence Areas
- Use of Network Analysis Methods to Characterize M. tuberculosis Transmission Patterns Among Women and Other High-Risk Populations
- An Analysis of Molecular Epidemiology of Multi-Drug Resistant M. tuberculosisin the United States
- Missed Opportunities for TB Prevention in Foreign-Born Population in the United States and Canada
- New Model for Assessing TB Surveillance and Action Performance and Cost
- Addressing TB Among African Americans in the Southeast: Identifying and Overcoming Barriers to Treatment Adherence for Latent TB Infection and TB Disease
- Assessing the TB Knowledge, Attitudes, Beliefs, and Practices Among Private Providers Serving Foreign-born Populations at Risk for TB
- Factors Associated with Acceptance of, Adherence to and Toxicity From Treatment for Latent TB Infection and Pilot Study of Treatment for Latent TB Infection Effectiveness
- Culturally Appropriate TB Educational Materials for Leaders and Staff of Hispanic Service Organizations
- Enhancing TB Programs’ Capacity for Self-Evaluation: Testing New Tools and Developing an Evaluation Toolkit
- African Refugee Women’s Health Improvement Project
- Evaluation of the TK Medium: A New Rapid Solid Culture System for Tuberculosis
- Evaluation of New Interferon-y Release Assays in the Diagnosis of Latent TB Infection in Health Care Workers
- Request for Proposal
- TB Trials Consortium
- Behavioral & Social Science Research
- TB Epidemiologic Studies Consortium
- Data & Statistics
- Education & Training
- Resources for TB Programs
- Publications & Products
- Fact Sheets
- General
- Fact sheets - Spanish
- TB - General Information
- The Difference Between Latent TB Infection and Active TB Disease
- Diferencia entre la infección de tuberculosis latente y enfermedad de tuberculosis activa
- A Global Perspective on TB
- Tuberculosis Information for Employers in Non-Healthcare Settings
- Bovine Tuberculosis in Humans
- Tuberculosis Information for International Travelers
- TB Can Be Treated
- Exposure to TB
- TB and HIV/AIDS
- You Can Prevent TB
- Testing for TB
- Tuberculosis: información general
- Diferencia entre la infección de tuberculosis latente y enfermedad de tuberculosis activa
- Información sobre la tuberculosis para los viajeros internacionales
- Exposición a la tuberculosis
- Usted puede prevenir la tuberculosis
- La tuberculosis puede ser tratada
- Tuberculosis y VIH/SIDA
- Usted puede prevenir la tuberculosis
- Pruebas para detectar la tuberculosis
- Data & Statistics
- A Global Perspective on TB
- Trends in Tuberculosis – United States
- The Revised Report of Verified Case of Tuberculosis
- The National Tuberculosis Indicators Project (NTIP)
- National Tuberculosis Indicators Project (NTIP): Frequently Asked Questions
- TB Genotyping
- TB Genotyping Information Management System (TB GIMS)
- Drug-Resistant TB
- Multidrug-Resistant Tuberculosis (MDR TB)
- Extensively Drug-Resistant Tuberculosis (XDR TB)
- CDC’s Role in Preventing Extensively Drug-Resistant Tuberculosis (XDR TB)
- Tuberculosis multirresistente (MDR)
- Tuberculosis extremadamente resistente (XDR)
- El papel de los CDC en la prevención de la tuberculosis extremadamente resistente (XDR)
- Infection Control & Prevention
- TB in Specific Populations
- Tuberculosis Information for Employers in Non-Healthcare Settings
- Tuberculosis in Minorities
- Tuberculosis Information for International Travelers
- TB and HIV/AIDS
- Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics
- Treatment of Drug-Susceptible Tuberculosis Disease in HIV-Infected Persons
- Tuberculosis in Blacks
- Tuberculosis and Pregnancy
- Tuberculosis y embarazo
- Treatment
- TB Can Be Treated
- Treatment of Latent TB Infection
- Treatment of Latent Tuberculosis Infection: Maximizing Adherence
- Treatment Options for Latent Tuberculosis Infection
- Treatment of Drug-Resistant Tuberculosis
- Treatment of Drug-Susceptible Tuberculosis Disease in Persons Not Infected with HIV
- Treatment of Drug-Susceptible Tuberculosis Disease in HIV-Infected Persons
- Tratamiento de la infección de tuberculosis latente
- Testing & Diagnosis
- TB Can Be Treated
- Testing for TB
- Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics
- Interferon-Gamma Release Assays (IGRAs)
- Tuberculin Skin Testing
- Diagnosis of Tuberculosis Disease
- Targeted Tuberculin Testing and Interpreting Tuberculin Skin Test Results
- Prueba cutánea de la tuberculina
- Diagnóstico de la tuberculosis activa
- Vaccines & Immunizations
- General
- Guidelines
- Guides & Toolkits
- Core Curriculum
- Self-Study Modules
- Report of Verified Case of Tuberculosis (RVCT)
- Forging Partnerships to Eliminate TB
- Understanding the TB Cohort Review Process
- Latent Tuberculosis Infection: A Guide for Primary Health Care Providers
- Effective TB Interviewing for Contact Investigation
- Mantoux Tuberculin Skin Testing Products
- Ethnographic Guides
- Newsletters
- Pamphlets, Brochures, Booklets
- Posters
- Mantoux Tuberculin Skin Test Wall Chart
- World TB Day
- Afiches
- 2011 Poster (English)
- 2011 Poster (Spanish)
- 2010 Poster (English)
- 2010 Poster (Spanish)
- 2008 Poster (English)
- 2008 Poster (Spanish)
- 2006 Poster (English)
- 2004 Poster (English)
- 2004 Poster (Spanish)
- 2003 Poster (English)
- 2003 Poster (Spanish)
- 2003 Now is the Time Poster (English)
- 2003 Now is the Time Poster (Spanish)
- Think TB
- Stop TB
- Reports & Articles
- Morbidity and Mortality Weekly Reports (MMWRs)
- Contact Investigations
- Control and Elimination
- Data & Statistics
- Drug-Resistant Tuberculosis
- Infection Control & Prevention
- Laboratory
- TB in Specific Populations
- Foreign-Born
- High-Risk Settings
- Homeless
- International
- Occupational Groups
- Travel
- TB & HIV
- Testing & Diagnosis
- Treatment
- LTBI Updates
- Vaccines & Immunizations
- World TB Day
- DTBE Authored Journal Articles
- Tuberculosis Laboratory Aggregate Reports
- Morbidity and Mortality Weekly Reports (MMWRs)
- Slide Sets
- Core Curriculum
- Self-Study Modules
- Prevention and Control of Tuberculosis in Correctional and Detention Facilities
- Guidelines for Preventing the Transmission of M. TB in Health care Settings
- Investigation of Contacts of Persons with Infectious TB
- Text-Only version
- Introduction
- Decisions to Initiate a Contact Investigation
- Investigating the Index Patient and Sites of Transmission
- Assigning Priorities to Contacts
- Diagnostic and Public Health Evaluation of Contacts
- Medical Treatment for Contacts with LTBI
- When to Expand a Contact Investigation
- Communicating Through the News Media
- Data Management and Evaluation of Contact Investigations
- Confidentiality and Consent in Contact Investigations
- Staff Training for Contact Investigations
- Contact Investigations in Special Circumstances
- Source-Case Investigations
- Cultural Competency and Social Network Analysis
- Resources
- Epidemiology of Pediatric Tuberculosis in the United States
- Text-Only version
- Introduction
- Pediatric TB Cases by Age and Race
- Pediatric TB Cases by Origin of Birth
- Pediatric Cases, Percentages and Rates by States
- Pediatric TB Cases by Case Verification Criterion and Site of Disease
- Pediatric TB Cases in Specific Groups
- Pediatric TB Cases Case Completion
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Treatment of TB
- Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
- CD Roms
- Electronic Tools & Resources
- Web-Based Courses & Webinars
- Content Syndication
- Fact Sheets
- Global TB
- Events
- Links
- About Us
- Mission Statement and Activities
- Organization Chart
- Advisory Groups
- Federal TB Task Force
- Table of Contents
- Executive Summary
- Introduction
- Chronology in the Development of This Report
- Strategies for Maintaining Control of TB
- Strategies for Accelerating the Decline of TB
- Activities for Developing New Tools
- Global U.S. Actions
- Assessing the Impact of Actions Taken
- Federal TB Task Force Members and Others Involved in the Development of This Report
- Glossary
- References
- Federal TB Task Force Roster
- Table of Contents
- Executive Summary
- Introduction
- How to Eliminate TB? – The IOM Report
- Why Eliminate TB? – Rationale for Elimination
- Who Will Lead? – CDC's Response
- Goal I: Maintain control of TB
- Goal II: Accelerate the decline
- Goal III: Create new tools
- Goal IV: Reduce the global burden of TB
- Goal V: Summon and sustain support
- Goal VI: Track progress
- References
- Federal TB Task Force
- Funding


